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G-quadruplexes (G4) are secondary nucleic acid structures that have been associated with genomic 
instability and cancer progression. When present in the promoter of some oncogenes, G4 structures 
can affect gene regulation and, hence, represent a possible therapeutic target. In this study, RNA-Seq 
was used to explore the effect of a G4-binding anthraquinone derivative, named AQ1, on the whole-
transcriptome profiles of two common cell models for the study of KIT pathways; the human mast cell 
leukemia (HMC1.2) and the canine mast cell tumor (C2). The highest non-cytotoxic dose of AQ1 (2 µM) 
resulted in 5441 and 1201 differentially expressed genes in the HMC1.2 and C2 cells, respectively. In 
both cell lines, major pathways such as cell cycle progression, KIT- and MYC-related pathways were 
negatively enriched in the AQ1-treated group, while other pathways such as p53, apoptosis and 
hypoxia-related were positively enriched. These findings suggest that AQ1 treatment induces a similar 
functional response in the human and canine cell models, and provide news insights into using dogs as a 
reliable translational model for studying G4-binding compounds.
Targeted therapy is a novel strategy for cancer treatment that aims to destroy cancer cells with more precision 
and, potentially, fewer side effects1. For the discovery of clinical agents targeting oncogenic signaling pathways, it 
is important to define the compound’s specificity towards the target molecular pathway. In this respect, the field 
of cancer genetics and genomics is rapidly evolving, particularly focusing on targeted pathways that are critically 
linked to a malignant behavior2. Currently, multiple compounds are being used to treat cancer and many more 
are being tested in clinical trials3–5.
Canine/human comparative oncology is recently playing an increasingly important role in advancing can-
cer research from basic science, preclinical and clinical perspectives. The acknowledgment of spontaneous can-
cer development in companion animals and the potential of using these animals in drug development studies 
and preclinical trials is harnessed by the morphologic, histologic and biological similarities between canine and 
human spontaneously-occurring malignancies. Dogs’ physical size, accessibility to serial biological sample collec-
tions, comparable tumor biology, intact immunity and short survival compared to humans led to their inclusion 
as a complementary animal model2. Inter-species cancer studies have contributed to gaining new insights into 
the biology of breast cancer, osteosarcoma, lung and bladder cancer6–10. Further, recent studies on canine B-cell 
lymphoma demonstrated that recurrent aberrations were correlated with cancer subtype, and the correspond-
ing cytogenetic lesions were also noticed in human patients11,12. Meantime, another study showed that canine 
melanoma possesses rare mutations in the B-Raf (BRAF) and N-ras (NRAS) proto-oncogenes; however, they 
present similar gene expression changes to human melanoma within the same downstream activation pathways13. 
Thus, although the oncogenic driving somatic mutations between the two species may differ, similar upregula-
tion and signaling pathways underscore the translational value of studying tumor biology from a comparative 
point of view. This concept might support the beginning of the so-called ‘oncological basket’ trials, wherein the 
response of tumors with shared credentialed biology to a specific targeted therapy are assessed beyond histologic 
diagnosis2.
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In the past decade, several studies have been focusing on guanine-rich stretches found in important genomic 
regions such as telomeres, centromeres, immunoglobulin switch regions, mutational hot spots, and promoter ele-
ments14. These guanine-rich sequences may have the potential to form four-stranded secondary structures called 
G-quadruplexes (G4) that are stabilized by non-Watson-Crick interactions (Hoogsteen bond15). Several studies clari-
fied that G4 structures are often linked to important DNA regions involved in the regulation of gene transcription and 
translation16,17. Moreover, studies have shown that several proto-oncogenes like v-myc avian myelocytomatosis viral 
oncogene homolog (MYC), v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT), B-cell lymphoma 
2 (BCL2), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and hypoxia-inducible 
factor (HIF) bear G4 motifs in their promoters16,18–24. Specific proteins, which selectively bind G4 structures, have been 
discovered impinging on the biological roles of G425. These motifs could be efficiently targeted by G4-selective ligands, 
thus altering their molecular recognition and, consequently, affect their downstream expression25.
More than 55% of the genes in the human genome bear at least one potential G4 motif 1 kb up- or downstream 
of the transcription starting site (TSS); hence, it is important to carefully assess whether the treatment with G4 
binding compounds could affect the transcriptional activity of these genes26. Using the G4-stabilizing molecule 
TMPyP4, previous studies showed genome-wide effects on transcription in human cells; moreover, relatively high 
doses of TMPyP4 promoted cell migration and apoptosis in human cell lines27–29. Likewise, Halder and colleagues 
demonstrated that bisquilinium compounds were able to induce quadruplex-specific transcriptomic changes in 
HeLa S3 cells26. Marchetti et al., in 2018, used the RNA-Seq technology to study the effects of a new G4 binding 
compound in pancreatic ductal adenocarcinoma30.
Recently, we demonstrated that an anthraquinone derivative (named AQ1, Supplementary Fig. S1) significantly 
downregulated KIT mRNA and protein levels in several human cancer cell lines, thereby preventing their pro-
liferation31. Meantime, two KIT G4-forming sequences (d_kit1 and d_kit2) were discovered in the canine genome 
(Supplementary Fig. S1)32. They showed a high degree of homology with the corresponding human sequences, and 
preliminary studies were conducted to assess their interaction with AQ133. These studies on G4 structures were exe-
cuted using a targeted-gene approach; nevertheless, it is of interest to extend the study of AQ1 transcriptional effects 
to a wider scenario, like the whole-transcriptome. Such an approach is expected to: (1) clarify the AQ1 influence on 
KIT-related pathways and (2) unveil specific off-targets of AQ1 in species-specific cells. Therefore, in the present 
study, we investigated - using RNA-Seq- the AQ1-induced effects on the global gene expression in two species-specific 
KIT-dependent cancer cell lines, in order to identify which cellular pathways are likely to be affected by treatment. For 
this purpose, we used the HMC1.2 human mast cell leukemia and the C2 canine mast cell tumor cell line, which are two 
common models for the study of tyrosine kinase inhibitors and, in particular, the proto-oncogene KIT.
Results
Effects of AQ1 on cell cytotoxicity and KIT and BCL2 mRNA levels. We previously demonstrated 
that AQ1 significantly downregulated KIT and BCL2 oncogenes in human mast cell leukemia HMC1.2, where the 
major effect of the treatment was observed 12 hours (T12) post-exposure31. Thus, we selected this incubation time 
to follow the activity of AQ1 on the two cell lines used in this study. Proliferation curves (Supplementary Fig. S2) 
demonstrated that, after 12 hours of incubation, AQ1 was moderately cytotoxic, with 70–90% cell survival in both 
the two cell lines at the tested concentration range (0–10 μM). Additionally, quantitative real-time PCR (qPCR) 
showed a significant dose-dependent reduction of KIT and BCL2 mRNA levels in both HMC1.2 (p < 0.01) and 
C2 (p < 0.001) cells (Supplementary Fig. S3).
Whole-transcriptome profiling. To account for any possible vehicle- (dimethyl sulfoxide, DMSO) related 
effects on cell gene expression, we also profiled the transcriptome of untreated cells (treatment- and vehicle-free 
medium). No differentially expressed genes (DEGs) were detected in the DMSO-treated cells compared with the 
untreated ones (results not shown); consequently, the DMSO-treated cells dataset was used as control.
The RNA-Seq analysis of the AQ1-treated HMC1.2 cells, compared with DMSO-treated cells, evidenced 3644 
and 5441 DEGs (false discovery rate, FDR <0.05 and fold-change, FC >2) at 1 µM and 2 µM AQ1 concentrations, 
respectively. For both concentrations, more than 60% of the total DEGs were downregulated. In the AQ1-treated 
C2 cells, the whole-transcriptome analysis identified 397 and 1201 DEGs at 1 µM and 2 µM AQ1 concentration, 
respectively. Likewise to HMC1.2, more than 70% of these DEGs were downregulated. The whole list of the 
DEGs for both cell lines is reported in Supplementary Dataset S1 and a list of the common downregulated genes 
between HMC1.2 and C2 is reported in Supplementary Dataset S2.
Both experimental groups clustered uniquely on a hierarchical clustering plot (Fig. 1a,b), and a Principal 
Component Analysis (PCA) plot, using the top 100 DEGs, resulted into two distinct clusters of samples with the 
principal component 1 (PC1) accounting for the major variation between groups (PC1 >98%; Fig. 1c,d). This 
variation between AQ1-treated and control groups is further visualized using two heatmaps that are shown in 
Supplementary Fig. S4.
Gene set enrichment analysis (GSEA) and protein-protein interactions. Canine C2 and human 
HMC1.2 cell lines showed similar functional response to AQ1 treatment. Figures 2 and 3 show the most positively- 
or negatively-enriched cancer hallmarks in the AQ1-treated (2 µM) HMC1.2 (Fig. 2) and C2 cells (Fig. 3). In 
HMC1.2 cells (Fig. 2), the most negatively-enriched hallmarks were the mTORC1 signaling pathway (FDR = 0.017), 
the targets of MYC (FDR = 0.026), the G2M cell cycle checkpoint (FDR = 0), and the mitotic spindle (FDR = 0). As 
shown in Fig. 3, AQ1-treated canine C2 cells show a similar functional response to the human HMC1.2 cells. Further, 
KEGG pathways analysis (Supplementary Tables S1–S4) identified many pathways that were negatively-enriched in 
the AQ1-treated samples, in both cell lines34–36. For instance, cell-cell adherent junctions (HMC1.2, FDR = 0.009; 
C2, FDR = 0.043), mismatch repair (HMC1.2, FDR = 0.015; C2, FDR = 0.041), the regulation of actin cytoskeleton 
(HMC1.2, FDR = 0.012; C2, FDR = 0.036), the DNA replication machinery (FDR = 0.008), the tRNA biosynthesis 
www.nature.com/scientificreports/
3SCIentIFIC REpoRtS |         (2018) 8:17107  | DOI:10.1038/s41598-018-35516-y
(FDR = 0.012) and the cell cycle pathway (FDR = 0.014). Figure 4 (panels a,b) shows the downregulation of phos-
phatidylinositol signaling system (p ≤ 0.001) KEGG pathway in HMC1.2 and C2, respectively. Moreover, the 
complement and coagulation cascade were the most important KEGG pathway positively enriched in both cells 
(Fig. 4c,d). Supplementary File 1 report, more in details, the most important pathways identified by KEGG GSEA 
analysis in HMC1.2 and C2, respectively. This functional similarity was also confirmed by the The Database for 
Annotation, Visualization and Integrated Discovery (DAVID) tool (data not shown). Also, several important cancer 
hallmarks, such as P53- and apoptosis-related pathways as well as hypoxia and tumor necrosis factor α (TNFα) 
pathways related to NF-κβ, were positively enriched (FDR < 0.05) in both cell lines (Figs 2 and 3).
With regard to KIT regulation, the RNA-Seq data evidenced a significant inhibition of multiple downstream 
processes activated by this proto-oncogene. Figure 5 shows the expression profile (mRNA) of some genes that are 
part of several KIT downstream pathways such as the Ras/Erk signal transduction, the PI3K signal transduction, 
the PLC-γ signaling transduction, the Src kinase signal transduction and the JAK/STAT signaling pathways37. In 
both cell lines, the whole set of target genes were negatively enriched following the AQ1 treatment, except for the 
canine JAK-STAT pathway.
To uncover some of the biological consequences the DEGs might have, the top downregulated protein-coding 
genes were collapsed to their corresponding protein symbols and their interactions were visualized by a 
protein-protein interaction (PPI) network, using the Search Tool for the Retrieval of Interacting Genes/Proteins 
(STRING, https://string-db.org/) database. Figure 6 shows the PPI network (p < 0.001) observed in HMC 1.2 cells 
exposed to 2 µM AQ1. The most negatively-enriched pathways were the transmembrane receptor protein tyrosine 
kinase signaling pathway (GO.0007169; FDR <0.001), the vascular endothelial growth factor receptor signaling 
pathway (GO.0048010; FDR <0.001), and the cell surface receptor signaling pathway (GO.0007166; FDR <0.001). 
Because the STRING database relies largely on curated experimental data, a meaningful PPI for the DEGs of C2 cells 
was not possibly – likely because little information is available on the function of proteins in dogs.
Figure 1. Analysis of intra-population consistency: hierarchical clustering and PCA. (a,b) Hierarchical 
clustering analyses performed using DESeq2 rlog-normalized RNA-Seq data. (a) HMC1.2 cells, AQ1 (2 µM) vs 
DMSO. (b) C2 cells, AQ1 (2 µM) vs DMSO. Color code (from white to dark blue) refers to the distance metric 
used for clustering (dark blue corresponds to the maximum of correlation values). (c,d) Principal Component 
Analysis (PCA) performed on top 100 differentially expressed genes using ClustVis (Metsalu & Vilo, 2015) tool. 
Loadings PC1 and PC2 are reported in graph (on x and y-axes). (c) HMC1.2 cells, AQ1 (2 µM) vs DMSO. (d) C2 
cells, AQ1 (2 µM) vs DMSO.
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G4 prediction. The Quadbase2/EuQuad tool38,39 was used to mine G4 from RNA-Seq results using the corre-
sponding gene’s Ensembl ID. Figure 7 reports the results obtained searching for the G3 L1–7 motif in ±2 kb TSS 
of each record. In both species, EuQuad predicted the presence of at least one G4 domain near the TSS for the 
majority of DEGs (overall >75%). The percentage of DEGs with a predicted G4 domain did not differ between 
the down- and up-regulated genes (71% vs 85.8% in canine DEGs and 80% vs 76% in human DEGs, respectively).
Figure 2. GSEA cancer hallmarks positively and negatively enriched after treatment with 2 μM AQ1 in 
HMC1.2 cells. The x-axis reported the gene group size and numbers at the end of the bars represented NES 
value.
Figure 3. GSEA cancer hallmarks positively and negatively enriched after treatment with 2 μM AQ1 in C2 cell 
line. The x-axis reported the gene group size and numbers at the end of the bars represented NES value.
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qPCR confirmation. To cross-validate the RNA-Seq data, twelve genes were tested for their relative gene 
expression by qPCR. The selected genes belonged to different pathways: KIT activation pathways (RPTOR), epige-
netic regulation (HDAC4), apoptosis (BMF), cell cycle (CDKN1A, CDK6), metabolism (CYP1A1, FAXDC2), cell 
signaling (KRS2, TNFRSF11β), transcription regulation (EGR2), cell morphology (MID1), and tumor oncogenes 
(EGFR). The qPCR results (Supplementary Figures S5–S7) corroborated the RNA-Seq data analysis. In specific, 
the downregulation of RPTOR and HDAC4 by AQ1, as well as the upregulation of the pro-apoptotic factor BMF 
and cell cycle controller CDKN1A were significantly correlated between the qPCR and RNA-Seq data, in both 
cell lines.
The EuQuad output for each gene selected for qPCR confirmation is shown in Supplementary Table S5. For 
every gene, the software analyzed around 2 kb before and after the TSS to search for G3 L1-7 motif. HDAC4 was 
the gene with the highest number of putative G4-forming sequences near the TSS in both species, followed by 
CDK6 in human and RPTOR in dog. On the contrary, for other genes like canine EGFR, human CDKN1a and 
human EGR2 the tool did not find G3 L1-7 motifs.
Discussion
DNA is one of the main targets of most anticancer drugs. However, it is rather difficult to achieve a selective effect 
on particular DNA regions because of the high homogeneity of cellular DNA, mostly occurring in the B form. 
Interestingly, the possible interactions with specific non-canonical DNA structures may improve the selectivity 
of low molecular weight compounds towards certain cell processes or signaling pathways. In this scenario, an 
increasing interest has recently gained targeting the G4 secondary structure of nucleic acids that might affect 
pathways that are critical for tumor cells growth and proliferation40.
Figure 4. GSEA Enrichment plot (KEGG pathways) negatively and positively enriched in HMC1.2 and C2 
cell lines exposed to AQ1 2 μM. The phosphatidylinositol signaling system was negatively enriched by AQ1 
in HMC1.2 (panel a) and C2 (panel b). The complement and coagulation cascades pathways was positively 
enriched by AQ1 in HMC1.2 (panel c) and C2 (panel d). The green curve corresponds to the ES (enrichment 
score) curve, which is the running sum of the weighted enrichment score obtained from GSEA software, 
while the normalized enrichment score (NES) and the corresponding FDR are reported within each graph. A 
permission for the use of the images was obtained by KEGG (Kanehisa Laboratories rif. 180271)34–36.
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We previously used a targeted approach to assess the effect of AQ1 both in human and canine KIT-dependent 
cell lines (from two to almost forty-fold inhibition)31–33. Results demonstrated a significant inhibition of cell 
proliferation and downregulation of KIT and BCL2 induced by AQ1 whereas other prototypical oncogenes as 
hTERT, MYC, and PDGF were not highly modulated by this compound. Moreover, we confirmed the presence of 
two conserved G4 forming domain in canine cKIT promoter32.
Taking into consideration these evidence, in the present study, we profiled, using RNA-Seq, the effects of 
AQ1 treatment on the transcriptome of two KIT-dependent cell lines of human and canine origin (HMC1.2 and 
C2, respectively). The choice of time and doses derived from a preliminary validation step; in particular, the two 
doses we used were poorly cytotoxic for both cell lines, while the time of exposure (T12) was sufficiently short to 
attribute the major transcriptional modulation to DNA binding by AQ1 and not to secondary effects that could 
occur over a longer treatment time. Indeed, the occurrence of such a drawback emerged in previous transcrip-
tional works. For instance, Halder and colleagues (2012) performed a transcriptional profiling with microarray 
after 48 h of treatment; because of the long-time of treatment, it was not possible to rule out whether or not some 
or many of the observed effects were attributed to a direct G4 formation or to secondary effects26. Furthermore, 
HeLa S3 and K562 cells exposed to the G4-stabilizing molecule TMPyP4, showed genome-wide transcriptional 
effects. However, a smaller set of affected genes (69 and 87 genes for HeLa S3 and K562 cells, respectively) were 
identified at prolonged (48 h) time of exposure to relatively high TMPyP4 concentration27,28 (100 μM).
In this study, upon cell treatment with AQ1, we noticed a dose-dependent increasing number of DEGs; more-
over, an overall major inhibitory transcriptional effect was observed in both cell lines. This is in line with several 
studies indicating G4 as a transcription suppressor element41–43. The ligand-induced stabilization of G4 motifs 
could lead to “jamming” of the transcription bubble, thus resulting in stalling of RNA polymerase and in an 
aborted transcription27,44. This is also in agreement with the suppression of gene expression that we observed in 
our experimental conditions. The use of EuQuad clarified that most of up- or downregulated DEGs possessed at 
least one G3 L1-7 motif near the TSS. Nevertheless, this is just an in-silico prediction and other approaches, e.g. 
the Chem-seq technique and G4-Seq or G4 ChIP-seq methods, could give more precise information about AQ1 
and G4 interactions on the whole genome level45–47.
On a comparative basis, we observed a higher number of DEGs in the human versus the dog cell line. This 
result supports preliminary analysis on C2 cells where a slight reduction of KIT mRNA and protein levels was 
observed upon treatment with AQ133. This can be reasonably connected to the different sequence and distri-
bution of the G4 forming domains in the human versus canine promoters although the modulation of distinct 
cellular pathways cannot be ruled out. Indeed, a critical issue might be represented by the fact that the two cell 
lines we used in this study represent, in both species, suitable in vitro models for mast cell diseases. However, 
they derive from different neoplasms, i.e. human mastocytosis (HMC 1.2) and cutaneous mast cell tumor (C2). 
Hence, this study does not represent a mere transcriptome comparison between the two species since apparent 
contradictions might result from gene and/or pathways differential expression in the two cell lines. However, 
despite the possible presence of substantial transcriptional differences between the two cell lines, several common 
cancer hallmarks and oncogene-related pathways were identified. In particular, the mTOR- and MYC-dependent 
pathways were downregulated in both species, whereas the apoptosis and p53-mediated programmed cell death 
were positively enriched. Other ligands have already been investigated for their ability to stabilize the G4 structure 
of MYC and KIT promoter, thereby affecting their downstream pathways. In Goh et al. (2016), a salicylaldehyde 
Figure 5. RNA-Seq fold change (FC) of genes involved in KIT downstream pathways after treatment with 
AQ1 2 µM. GRB2: Growth Factor Receptor Bound Protein 2. MAPK: Mitogen-Activated Protein Kinase 1. 
AKT3: AKT Serine/Threonine Kinase 3. mTOR: Mechanistic Target Of Rapamycin Kinase. FYN: FYN Proto-
Oncogene, Src Family Tyrosine Kinase. PLCγ2: Phospholipase C Gamma 2. SOS1: SOS Ras/Rac Guanine 
Nucleotide Exchange Factor 1. BRAF: B-Raf Proto-Oncogene, Serine/Threonine Kinase. LYN: LYN Proto-
Oncogene, Src Family Tyrosine Kinase. JAK2: Janus Kinase 2. STAT: Signal Transducer And Activator Of 
Transcription 1.
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semicarbazone copper (II) complex induced apoptosis through the caspase-dependent pathway by reducing the 
expression of RAS and MYC, and by inhibiting Ras-ERK and PI3K-Akt pathways in MOLT-4 leukemia cells48. In 
2013, Shen and colleagues proved that a G4 ligand named SYUIQ-FM05 suppressed KIT mRNA transcription 
and total kit protein amount in K562 cells, and this inhibition led to a downregulation of MEK activity, ERK 
phosphorylation, and the RAS/MEK/ERK signaling pathway49.
If we consider as a whole the GSEA hallmarks and KEGG pathways upregulated by AQ1, there is a predom-
inance of immune system-related pathways. In this respect, no information is available on the stimulation of 
immune system by other G4 ligands; hence, this could represent an interesting and positive aspect to be consid-
ered in further studies.
Assuming a major effect of AQ1 at oncogenes promoters possessing G4 structures, we analyzed the most 
important pathways regulated by some of the most common oncogenes, such as MYC, BCL2, PDGF, hTERT and 
VEGF. Considering MYC-related pathway, AQ1 caused the downregulation of E2F, MDM2, p53, p73 and BCL6 
in HMC1.2 cells. Interestingly, the latter two genes showed a similar behavior also in canine cells. BCL2 was 
Figure 6. STRING protein network map of thirty proteins commonly downregulated by AQ1 2 µM in HMC1.2. 
Colored nodes indicate the individual protein identified. Lines between nodes represent direct and indirect 
association of proteins. Line colors indicate the type of interaction evidence (light blue: known interaction from 
curated database; purple: known interaction experimentally determined; green: predicted interaction gene 
neighborhood; red: predicted interaction gene fusion; blue: predicted interaction gene co-occurrence; yellow: 
text mining; black: co-expression; lilac: protein homology.
Figure 7. Number of DEGs that are predicted by EuQuad tool to have at least one putative G-quad sequence in 
the region ±2 kb TSS (G3 L1-7).
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modulated by the AQ1 treatment in both cell lines with the consequent increase in apoptosis-related pathways 
confirmed by the increasing expression of pro-apoptotic factors as BIK, BMF and NOXA (the last one only in 
HMC1.2 cells). In general, it is well demonstrated as anthraquinone derivatives have been shown to induce apop-
tosis in vitro, and such a phenomenon usually implies a decrease of BCL2 mRNA/protein50–53. The PDGF signal-
ing pathway was affected only in HMC1.2 cells, with the downregulation of TIAM2, VAV1, VAV2 and NF-kβ. No 
variation in mRNA levels of TERT gene were noticed in both cell lines, despite the important role of G4 sequences 
in its regulation and transcription54. Finally, VEGF pathway was only partially influenced by AQ1 in human cells, 
as shown by caspase 9, GRB2 and SOS downregulation. In dog cell line, VEGF pathway was negatively enriched 
by GSEA, likewise to human.
Interestingly, in this study we identified new oncogenes affected by AQ1; for example, the gene FYN was 
downregulated in both cell lines. FYN is a tyrosine kinase proto-oncogene with a role in proliferation, invasion 
and migration in human thyroid carcinoma55,56. It also plays a critical role in the development, progression and 
resistance to anti-cancer drugs in breast cancer, prostate cancer and leukemia56. No information is available about 
the presence of G4 in its promoter sequence. On the other hand, two G4 forming sites are present in the human 
EGFR promoter57, a transmembrane protein activated by the epidermal growth factor and the transforming 
growth factor alpha (TGFα). This oncogene was downregulated by AQ1 only in dog, but other G4 ligands have 
been shown to affect its mRNA levels in a previous human transcriptomic study26.
The proto-oncogene JUN was upregulated in HMC1.2 (FC = 18) but not in canine cells. Consistent knowledge 
shows that c-jun contributes to tumor initiation and increased invasiveness58. However, few studies discovered 
some alternative activities of c-jun, suggesting that it may act as a double-edge sword in cancer58. As an example, 
c-jun seems to prevent methylation silencing of p16INK4a, a tumor suppressor and a cell cycle inhibitor gene59. 
Moreover, the anticancer mechanism of action of tylophorine, a plant-derived alkaloid, is mediated by c-jun, 
resulting in G1 cell cycle arrest in carcinoma cells, occurring through the downregulation of cyclin A260.
Despite the innovative results obtained in this study, several limitations should be considered. Probably, 
the most important one is the absence of a validation step for the RNA-Seq platform at the protein level. The 
post-transcriptional mechanisms of regulation and the emerging evidence that 5′- and 3′-untranslated regions 
(5′- and 3′-UTRs) as well as open reading frames (ORFs) contain putative RNA G4, might play an important role 
in tumor biology, e.g., switching on/off some tumor-related pathways61. From previous data, the AQ1-mediated 
downregulation of KIT was confirmed also at the protein level in human and canine in vitro models31–33. Hence, 
the protein evaluation of the kit-downstream pathways could substantiate current transcriptional results. 
Secondly, in the present study we considered one G4 ligand compound and only tumor cell lines. In perspective, 
it could be of interest to extend the RNA-Seq analysis also to a non-tumor cell line, to distinguish any non-specific 
effects. From previous information obtained in MDCK cells, these are much more resistant to AQ1 in term of 
cytotoxicity and survival33, but a more in-depth study investigating also non tumor-specific pathways is still miss-
ing. Finally, in terms of pathways analysis (DAVID), a limit derived by the actual scarce annotation of dog genome 
in comparison with the human one, and this should be consistently taken into consideration in the approach to 
future studies. Nevertheless, the present work represents the first step to validate dog as suitable translational 
model with reference to the use of G4-binding compounds.
In conclusion, the present study showed that AQ1 G4-binding compound inhibited KIT expression and its 
downstream signaling molecules GRB2, AKT and FYN in two in vitro models of human and canine mast cell 
neoplasms (HMC1.2 and C2 cells). Interestingly, besides KIT, AQ1 negatively affected the MYC-related pathway 
whereas it induced both apoptosis and P53-related pathways. Overall, these results suggest a possible role of AQ1 
in blocking mast cells proliferation via different pathways, thus representing a potential therapeutic target for 
comparative mast cell tumors.
Methods
All methods were carried out in accordance with relevant guidelines and regulations generally used for han-
dling human and animal cell lines in the Department of Comparative Biomedicine and Food Science and at the 
University of Padua.
Ligand. AQ1 was synthesized by Prof. G. Zagotto (University of Padua, Italy), and its chemical structure and 
affinity studies with h_kit1 and h_kit2 G4 sequences were previously published31. Stock solutions (10 mM) of the 
ligand were prepared in DMSO (Sigma-Aldrich Co., St. Louis, USA).
Cell culture. The human mast cell leukemia HMC1.2 expressing mutated KIT (D816V substitution) was 
kindly provided by Dr. Joseph Butterfield (Mayo Clinic, Rochester, MN, USA). The canine MCT cell line C2, 
expressing mutated KIT (48 bp internal tandem duplication in the juxtamembrane domain) was kindly provided 
by Dr. Patrice Dubreuil (Centre de Recherche en Cancérologie de Marseille, France). Cells were cultured in RPMI 
1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1% penicillin/streptomy-
cin (Gibco, Thermo Scientific, Waltham, USA). The C2 culture medium was supplemented with 1 mM sodium 
pyruvate.
Cell viability was checked by using the Trypan Blue dye exclusion test (Sigma-Aldrich Co., St. Louis, USA). 
For all the experiments, cells were used from passage 5 to passage 30. Cell cultures were screened routinely for 
Mycoplasma spp. contamination through PCR Mycoplasma Test Kit (PromoKine, Heidelberg, Germany).
For the dose-response assay, 2 × 104 cells were seeded in P96 well plates and treated with a range of doses com-
prised between 0.2 µM and 10 µM (final concentrations). Cell proliferation was assessed by CellTiter-Blue® Cell 
Viability Assay (Alamar Blue, Promega, Madison, USA) at T12. Fluorescence was measured at 560 nm (excitation 
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wavelength) and 590 nm (emission wavelength), by using a VICTOR™X4 Multilabel Plate Reader (Perkin Elmer, 
Waltham, USA). Three independent experiments were performed, and each concentration was tested six times.
Cell treatment and qPCR. Cells were seeded in 6-well plates (9 × 105 cells/well) and treated with two doses 
of AQ1 (1 µM and 2 µM) for 12 hours. For each experiment, we included also untreated and DMSO-treated cells. 
Five different experiments were conducted for each cell line.
Total RNA was extracted by RNeasy Mini Kit (Qiagen Italia, Milano, Italy). To reduce the possible presence 
of genomic DNA contamination, a 15-minutes on-column DNase digestion step was included in the RNA iso-
lation protocol. Total RNA concentration was determined using the NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies Inc., Wilmington, USA), and its quality was assessed using the 2100 Bioanalyzer and 
RNA 6000 Nano kit (Agilent Technologies, Santa Clara, CA, USA). The reverse-transcription of mRNA into 
cDNA were carried out as previously published31.
The list of primers used in the present study for qPCR analysis is reported in Supplementary Table S6.
Target genes to be tested in qPCR cross-validation assay were selected considering different expression trends 
in both cell lines. Specifically, we selected two genes that were downregulated (RPTOR and HDAC4) as well as two 
other ones that were shown to be upregulated (BMF and CDKN1A) in both cell lines. We also included two DEGs 
that were downregulated (EGFR and KRS2) and two genes upregulated (TNFRSF11b and FAXDC2) exclusively in 
C2 cell line; finally, two DEGs that were downregulated (CDK6 and MID1) and two genes upregulated (EGR2 and 
CYP1A1) exclusively in HMC1.2 cell line. Oligonucleotide primers were designed using the software UPL Assay 
Design Centre web service (Roche Diagnostics, Mannheim, Germany), and each assay specificity was evaluated 
in silico, by using the BLAST tool.
Quantitative real-time PCR reactions (10 µL final volume) were performed as previously reported28, using 
0.83 ng −1 ng of cDNA and 1–1.25 ng for C2 and HMC1.2, respectively. The analysis was conducted in a 
LightCycler 480 Instrument (Roche Applied Science, Indianapolis, IN) using standard qPCR conditions (95 °C 
for 10 min; 45 cycles at 95 °C for 10 s and at 60 °C for 30 s; 40 °C for 30 s). Calibration curves were performed using 
serial dilutions of a cDNA pool and corresponding values of slope, efficiency (E) and dynamic range are reported 
in Supplementary Table S7. The assays with an E (%) between 90% and 110% were considered efficient.
The obtained qPCR data were analyzed using the LightCycler480 software release 1.5.0 (Roche Applied 
Science, Indianapolis, USA) and the second derivative method; the relative quantification (RQ) was calculated 
with the ΔΔCt method62. For the normalization step, four internal control genes (ICGs) were used: for C2, the 
transmembrane BAX inhibitor motif containing 4 (CGI-119) and the CCZ1 vacuolar protein trafficking and 
biogenesis associated homolog (CCZ1); for HMC1.2, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
and the beta-2-microglobulin (ß2M). A cDNA pool was used as calibrator.
Library preparation and RNA-Seq analysis. Strand-specific RNA-Seq libraries were prepared using the 
SureSelect strand-specific mRNA library preparation kit (Agilent Technologies, Santa Clara, CA, USA) as per 
the manufacturer’s instructions. In brief, poly(A) RNA was purified from 1 µg of total RNA using two serial 
rounds of binding to oligo(dT) magnetic particles; then, fragmented RNA was reverse transcribed to generate 
cDNA. An Illumina-specific adaptor was sequentially ligated to the 3′ end of cDNA fragments, purified using 
the AMPure XP beads (Beckman Coulter, Brea, CA, USA), and finally PCR-amplified (13 cycles) using an appro-
priate indexing primer to allow further samples multiplexing. The PCR-amplified libraries were purified with 
the AMPure XP beads (Beckman Coulter, Brea, CA, USA) and, then, assessed for their quality and fragments 
distribution using the 2100 Bioanalyzer DNA 1000 assay (Agilent Technologies, Santa Clara, CA, USA). In the 
presence of adaptor-dimers (Electropherogram’s peak at 100 to 150-bp), another round of magnetic beads puri-
fication was performed. Libraries were quantified using both the Qubit® Fluorometer (Life Technologies, USA) 
and the qPCR-based NEBNext library quantification kit (New England BioLabs, UK). Finally, equimolar amounts 
of each ten index-tagged libraries were multiplexed together in one pool (total 4 pools) and then sequenced by an 
Illumina HiSeq4000 for 50 sequencing cycles. The raw 50 bp single-end sequences (Sanger/Illumina 1.9 encoding) 
were quality-controlled using FastQC v.0.11.4 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), the 
low-quality bases (quality scores <30) and the adaptor contamination (if present) were removed by Trimmomatic 
v.0.3663 using the parameters ‘LEADING:3 SLIDINGWINDOW:4:20 MINLEN:25′. In the quality control step, we 
eliminated one biological replicate that showed a non-sufficient output. The high-quality reads were mapped by 
HISAT2 v.2.0.564 against the Ensembl reference genomes of Canis lupus familiaris (CanFam3.1, ftp://ftp.ensembl.
org/pub/release-90/fasta/canis_familiaris/dna) or Homo sapiens (GRCh38, ftp://ftp.ensembl.org/pub/release-90/
fasta/homo_sapiens/dna/). The uniquely-mapped reads aligned to exons were counted with HTSeq v.0.6.1, then 
tested using the DESeq2 R package v.1.14.1 for the presence of DEGs65,66. Genes with a FDR less than 0.05 and a 
FC value more than 2 were considered as DEGs. The sequencing data associated with this project were deposited 
in the GenBank’s Gene Expression Omnibus (GEO) under the accession number GSE120272. The statistical 
analysis of RNA-Seq data was performed considering AQ1 (1 or 2 µM) versus DMSO in each cell line. In order to 
establish the congruency among biological replicates, a PCA and a hierarchical clustering were performed.
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